XTX Topco Ltd Takes Position in United Therapeutics Co. (NASDAQ:UTHR)

XTX Topco Ltd bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,012 shares of the biotechnology company’s stock, valued at approximately $1,278,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. ClariVest Asset Management LLC increased its stake in United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares during the period. V Square Quantitative Management LLC purchased a new stake in shares of United Therapeutics during the second quarter worth about $30,000. Innealta Capital LLC purchased a new position in United Therapeutics in the second quarter valued at about $33,000. Rise Advisors LLC purchased a new position in United Therapeutics in the first quarter valued at about $32,000. Finally, Benjamin F. Edwards & Company Inc. grew its stake in United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 117 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Wells Fargo & Company upped their target price on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. LADENBURG THALM/SH SH lowered shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Bank of America reduced their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research note on Thursday, August 1st. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. Finally, Oppenheimer increased their price target on shares of United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $350.36.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $353.00 on Friday. The stock has a market capitalization of $15.70 billion, a P/E ratio of 16.69, a P/E/G ratio of 1.25 and a beta of 0.57. The firm’s 50-day moving average price is $338.55 and its two-hundred day moving average price is $290.39. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $366.08. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). The company had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same period last year, the business posted $5.24 EPS. As a group, sell-side analysts forecast that United Therapeutics Co. will post 24.86 earnings per share for the current year.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $315.97, for a total value of $1,137,492.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $41,076.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CFO James Edgemond sold 7,785 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the transaction, the chief financial officer now owns 2,615 shares of the company’s stock, valued at $947,597.55. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $315.97, for a total transaction of $1,137,492.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $41,076.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 110,922 shares of company stock valued at $36,541,398. 12.50% of the stock is currently owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.